

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TCL ELECTRONICS HOLDINGS LIMITED

TCL 電子控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01070)

(the “**Company**”, together with its subsidiaries, the “**Group**”)

ANNOUNCEMENT

PURSUANT TO RULES 13.51(2)(U) AND 13.51B(2) OF THE LISTING RULES

This announcement is made by the Company pursuant to Rule 13.51B(2) of the Rules Governing the Listing of Securities (“**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) in relation to a change in particulars under Rule 13.51(2)(u) of the Listing Rules of Mr. LAU Siu Ki (“**Mr. LAU**”), an independent non-executive director of the Company.

On 1 November 2019, the Company was informed by Mr. LAU that he has been named as one of six individuals against whom the Securities and Futures Commission (“**SFC**”) has commenced proceedings (“**Proceedings**”) in the Market Misconduct Tribunal (“**MMT**”). The SFC alleged that a breach of the disclosure requirements (the “**Allegations**”) within the meaning of sections 307B and 307G of Part XIVA of the Securities and Futures Ordinance (“**SFO**”) had or might have taken place in relation to the securities of China Medical & HealthCare Group Limited (“**CMHG**”, a company whose shares are listed on the Stock Exchange with stock code: 383 and which was known as COL Capital Limited at the material time). The Proceedings involve CMHG and six individuals who were then directors of CMHG, including Mr. LAU, being an independent non-executive director of CMHG at the material time.

Mr. LAU has informed the Company that he denies and intends to defend vigorously against the Allegations. The Allegations or the Proceedings have no relationship whatsoever with the Group’s businesses and/or operations, directors of the Company other than Mr. LAU, the senior management of the Company, or the Company’s shares and/or other securities. The Company does not consider that the Proceedings will have any material adverse impact on the Group’s businesses and/or operations.

As at the date of this announcement, the Proceedings are on-going and the MMT has yet to hear or determine whether a breach of the SFO has taken place or the identity of any person involved in the relevant breach. In the meantime, and until the Proceedings conclude, no findings in the Proceedings have been made in respect of Mr. LAU.

The Company will make further announcement(s) in relation to the above matters as and when appropriate in accordance with the Listing Rules.

On behalf of the Board
LI Dongsheng
Chairman

Hong Kong, 5 November 2019

As at the date of this announcement, the Board comprises Mr. LI Dongsheng, Mr. WANG Cheng Kevin, Mr. YAN Xiaolin and Mr. WANG Yi Michael as executive directors, Mr. Albert Thomas DA ROSA, Junior, Mr. YANG Anming and Mr. LI Yuhao as non-executive directors and Mr. Robert Maarten WESTERHOF, Dr. TSENG Shieng-chang Carter, Professor WANG Yijiang and Mr. LAU Siu Ki as independent non-executive directors.